Exact Sciences Corp [EXAS] stock is trading at $56.94, up 0.92%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EXAS shares have gain 6.63% over the last week, with a monthly amount glided 36.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Exact Sciences Corp [NASDAQ: EXAS] stock has seen the most recent analyst activity on April 10, 2025, when Mizuho initiated its Outperform rating and assigned the stock a price target of $60. Previously, RBC Capital Mkts started tracking the stock with Sector Perform rating on March 13, 2025, and set its price target to $52. On January 23, 2025, Barclays initiated with a Overweight rating and assigned a price target of $70 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $75 on August 28, 2024. Scotiabank initiated its recommendation with a Sector Outperform and recommended $70 as its price target on June 27, 2024. In a note dated January 02, 2024, The Benchmark Company upgraded an Buy rating on this stock but restated the target price of $91.
Exact Sciences Corp [EXAS] stock has fluctuated between $39.97 and $72.83 over the past year. Currently, Wall Street analysts expect the stock to reach $65 within the next 12 months. Exact Sciences Corp [NASDAQ: EXAS] shares were valued at $56.94 at the most recent close of the market. An investor can expect a potential return of 14.16% based on the average EXAS price forecast.
Analyzing the EXAS fundamentals
Exact Sciences Corp [NASDAQ:EXAS] reported sales of 2.83B for the trailing twelve months, which represents a growth of 10.86%. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.37%, Pretax Profit Margin comes in at -0.36%, and Net Profit Margin reading is -0.36%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.36 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Exact Sciences Corp’s Current Ratio is 2.73. As well, the Quick Ratio is 2.38, while the Cash Ratio is 0.69. Considering the valuation of this stock, the price to sales ratio is 3.80, the price to book ratio is 4.48.
Transactions by insiders
Recent insider trading involved Conroy Kevin T, President and CEO, that happened on Nov 13 ’24 when 19500.0 shares were purchased. EVP, GM, Precision Oncology, Baranick Brian completed a deal on Oct 08 ’24 to sell 929.0 shares. Meanwhile, Officer Baranick Brian bought 929.0 shares on Oct 08 ’24.
